Veenat 100 mg is a new generation drug that belongs to the pharmacological group of antineoplastic agents. Its cytotoxic properties are determined by the nature of the effect on the specific mutated enzyme-BCR-ABL-dependent tyrosine kinase, which is an important product for tumor growth in chronic myelogenous leukemia. The article describes detailed information about the drug, which is not an indication for self-treatment. Admission should only be carried out by the doctor’s prescription!

https://emedkit.com/product/veenat-100-imatinib/